Literature DB >> 23783165

Putative association of ABCB1 2677G>T/A with oxycodone-induced central nervous system depression in breastfeeding mothers.

Jessica Lam1, Lauren Kelly, Ilan Matok, Colin J D Ross, Bruce C Carleton, Michael R Hayden, Parvaz Madadi, Gideon Koren.   

Abstract

OBJECTIVE: To assess the effect of maternal CYP2D6, CYP3A5, ABCB1, and OPRM1 polymorphisms in predicting both neonatal and maternal central nervous system depression after oxycodone use during lactation. STUDY
DESIGN: A nested case-control study in 67 breastfeeding mother-infant pairs exposed to oxycodone was conducted. Cases were defined as parental reports of lethargy in the infant temporally related to oxycodone exposure via breastmilk. Maternal saliva samples were analyzed for 18 polymorphisms in 4 genes, CYP2D6, CYP3A5, OPRM1, ABCB1, involved in oxycodone metabolism and response.
RESULTS: Mothers of symptomatic infants were using oxycodone for a longer period of time during breastfeeding compared with those of asymptomatic infants (P < 0.0001). None of the maternal genetic variants in the 4 genes were associated with oxycodone-induced depression in neonates. However, mothers carrying at least one copy of the ABCB1 2677 T variant had an increased risk of experiencing sedation themselves (odds ratio, 2.35; 95% confidence interval, 1.06-5.28; P = 0.03).
CONCLUSIONS: The ABCB1 2677 T variant may predict oxycodone-induced central nervous system depression in breastfeeding mothers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23783165     DOI: 10.1097/FTD.0b013e318288f158

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

Review 1.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

2.  Sedating drugs and breastfeeding.

Authors:  Cheuk Kiu Chow; Gideon Koren
Journal:  Can Fam Physician       Date:  2015-03       Impact factor: 3.275

Review 3.  Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone.

Authors:  Mari Kinnunen; Panu Piirainen; Hannu Kokki; Pauliina Lammi; Merja Kokki
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

Review 4.  Pharmacogenomics of oxycodone: a narrative literature review.

Authors:  Nelly N Umukoro; Blessed W Aruldhas; Ryan Rossos; Dhanashri Pawale; Janelle S Renschler; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2021-03-17       Impact factor: 2.533

5.  Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).

Authors:  Maja Matic; Marga Nijenhuis; Bianca Soree; Nienke J de Boer-Veger; Anne-Marie Buunk; Elisa J F Houwink; Hans Mulder; Gerard A P J M Rongen; Jan van der Weide; Bob Wilffert; Jesse J Swen; Henk-Jan Guchelaar; Vera H M Deneer; Ron H N van Schaik
Journal:  Eur J Hum Genet       Date:  2021-07-15       Impact factor: 5.351

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.